M. Tanhapour, A. Golestani, A. Vaisi-Raygani, M. Aminian
{"title":"HB-EGF特异性抑制剂-交叉反应物质197及其抗癌作用","authors":"M. Tanhapour, A. Golestani, A. Vaisi-Raygani, M. Aminian","doi":"10.18502/bccr.v13i1.8828","DOIUrl":null,"url":null,"abstract":"Genetic heterogeneity and metastasis remain the most challenging aspects of cancer treatment.Recent studies have introduced a mutant of diphtheria toxin,cross-reacting material197 (CRM197), as a new promising biological anticancer drug to improve cancer therapy in patients previously resistant to chemotherapy. Weak toxicity of CRM197accounts forthe stimulation ofcell apoptosis and the antitumor effect. Increasing evidence has indicated that the expression of heparin-binding epidermal growth factor-like (HB-EGF) growth factorincreases in most cancer cells, and CRM197 is its specific inhibitor.This study has focused on the structure, properties, and anticancer activity of CRM197.","PeriodicalId":8706,"journal":{"name":"Basic & Clinical Cancer Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cross-Reacting Material 197, a Specific Inhibitor of HB-EGF, and Its Anticancer Effects\",\"authors\":\"M. Tanhapour, A. Golestani, A. Vaisi-Raygani, M. Aminian\",\"doi\":\"10.18502/bccr.v13i1.8828\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Genetic heterogeneity and metastasis remain the most challenging aspects of cancer treatment.Recent studies have introduced a mutant of diphtheria toxin,cross-reacting material197 (CRM197), as a new promising biological anticancer drug to improve cancer therapy in patients previously resistant to chemotherapy. Weak toxicity of CRM197accounts forthe stimulation ofcell apoptosis and the antitumor effect. Increasing evidence has indicated that the expression of heparin-binding epidermal growth factor-like (HB-EGF) growth factorincreases in most cancer cells, and CRM197 is its specific inhibitor.This study has focused on the structure, properties, and anticancer activity of CRM197.\",\"PeriodicalId\":8706,\"journal\":{\"name\":\"Basic & Clinical Cancer Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-02-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Basic & Clinical Cancer Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18502/bccr.v13i1.8828\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Basic & Clinical Cancer Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/bccr.v13i1.8828","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Cross-Reacting Material 197, a Specific Inhibitor of HB-EGF, and Its Anticancer Effects
Genetic heterogeneity and metastasis remain the most challenging aspects of cancer treatment.Recent studies have introduced a mutant of diphtheria toxin,cross-reacting material197 (CRM197), as a new promising biological anticancer drug to improve cancer therapy in patients previously resistant to chemotherapy. Weak toxicity of CRM197accounts forthe stimulation ofcell apoptosis and the antitumor effect. Increasing evidence has indicated that the expression of heparin-binding epidermal growth factor-like (HB-EGF) growth factorincreases in most cancer cells, and CRM197 is its specific inhibitor.This study has focused on the structure, properties, and anticancer activity of CRM197.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
